Concomitant External-beam Irradiation and Chemotherapy Followed by High-dose Rate Brachytherapy Boost in the Treatment of Squamous Cell Carcinoma of the Vagina: A Single-Center Retrospective Study

Anticancer Res. 2016 Apr;36(4):1885-9.

Abstract

Aim: To assess the outcome of 35 patients with vaginal carcinoma treated with different radiotherapy modalities.

Materials and methods: Thirty-one patients received external-beam irradiation (EBRT) to the entire vagina, para-vaginal area and pelvic nodes (total dose=45-50.4 Gy). Concomitant chemotherapy was used in 22 patients. Nineteen patients received additional 15-25 Gy high-dose-rate brachytherapy (BT) boost and eight received additional EBRT boost to the primary tumor site. Four women received exclusive 30-40 Gy high-dose-rate BT.

Results: Median progression-free survival and median overall survival were 22 months and 89 months, respectively. Age <70 years, use of EBRT plus BT, and concomitant chemotherapy were associated with better progression-free (p=0.002, p=0.007, and p=0.02) and overall (p=0.01, p=0.009, p=0.009) survival.

Conclusion: Concomitant EBRT and chemotherapy followed by BT is the best treatment for vaginal carcinoma.

Keywords: Vaginal carcinoma; brachytherapy; chemotherapy; external beam radiation; recurrence.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Brachytherapy* / adverse effects
  • Carboplatin / therapeutic use
  • Carcinoma, Squamous Cell / therapy*
  • Chemoradiotherapy*
  • Cisplatin / therapeutic use
  • Female
  • Fluorouracil / therapeutic use
  • Humans
  • Middle Aged
  • Paclitaxel / therapeutic use
  • Retrospective Studies
  • Vaginal Neoplasms / therapy*

Substances

  • Antineoplastic Agents
  • Carboplatin
  • Paclitaxel
  • Cisplatin
  • Fluorouracil